Firstly, we found that the MIT score was significantly positively correlated with the inflammatory and tumor-promoting immune cell gene expression signatures in most of the cancer types in addition to PDAC (Figure 6A), suggesting that MIT score may be used a pancancer biomarker to measure the PD1/PD-L1 independent crosstalk between malignant cell and immune cell. This evidence concerns the gene PDCD1 and neoplasm.